/PRNewswire/ Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announced financial.
As we kick off 2024, we reflect on regulatory developments in the biologics and biosimilars space in 2023. Below are some of the top regulatory developments from 2023.
Mike Crowther Appointed Chief Commercial and Business Strategy Officer
David Mitchell Appointed Senior Vice President, Head of Regulatory Affairs
Dan Calkins Promoted to Chief Financial Officer.
/PRNewswire/ Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing.
Second quarter results were impacted by weaker than expected global demand for capital equipment; clinical trial start delays; and slower than expected ramps from certain clientsSecond quarter.